Recurrent vulvovaginal candidiasis with Candida glabrata - a management conundrum.
Int J STD AIDS
; 33(10): 939-942, 2022 Sep.
Article
em En
| MEDLINE
| ID: mdl-35968569
ABSTRACT
High rates of azole-resistance and limited availability of pharmacological agents within the UK can make recurrent vulvovaginal candidiasis (RVVC) with Candida glabrata a challenging infection to treat. In this report, we describe our experience in managing C. glabrata RVVC and present the case of a patient with poor response to therapy and a protracted treatment course, spanning almost 4 years. We also highlight the need for evidence-based management protocols that consider the national availability of alternative treatments.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Candidíase Vulvovaginal
/
Candida glabrata
Tipo de estudo:
Diagnostic_studies
/
Guideline
Limite:
Female
/
Humans
Idioma:
En
Revista:
Int J STD AIDS
Assunto da revista:
SINDROME DA IMUNODEFICIENCIA ADQUIRIDA (AIDS)
Ano de publicação:
2022
Tipo de documento:
Article
País de afiliação:
Reino Unido